Anogen-Yes Biotech

08/05/2026

Encouraging data presented at AAIC 2026 highlight the growing potential of tau-targeted therapies in the treatment of early Alzheimer's disease.

Biogen's investigational antisense oligonucleotide diranersen (BIIB080) demonstrated:

🔬 50–65% reduction in cerebrospinal fluid (CSF) total tau levels
🧬 Significant reduction in brain tau pathology, measured by tau PET imaging
📉 Slowing of cognitive decline across multiple clinical endpoints, with the 60 mg dose showing the strongest benefit at 18 months
➡️ Advancement into Phase 3 clinical development following positive Phase 2 results

Unlike antibody therapies that target existing tau aggregates, diranersen is designed to reduce the production of all tau isoforms by targeting MAPT mRNA, representing a promising gene-silencing approach to Alzheimer's disease.

As research continues to expand beyond amyloid, advances in tau biology, biomarkers, and novel therapeutic strategies are opening new opportunities for Alzheimer's research and drug development.

At Anogen-Yes Biotech Laboratories, we are committed to supporting neuroscience research with high-quality antibodies, ELISA kits, and research reagents that help accelerate discoveries in neurodegenerative diseases.

Read the full article: https://biogen.gcs-web.com/news-releases/news-release-details/

07/29/2026

As Alzheimer's research continues to evolve, the spotlight at AAIC 2026 is shifting beyond amyloid to tau-targeted therapies, signaling an exciting new chapter in the search for disease-modifying treatments.

While anti-amyloid therapies such as Leqembi® remain the only approved disease-modifying treatments today, growing evidence suggests that tau pathology may play a more direct role in cognitive decline. Researchers are increasingly exploring therapies that target tau, with promising clinical programs from companies including Biogen, Eisai, Lilly, and Voyager Therapeutics.

Key trends emerging from AAIC 2026 include:

🔹 Growing momentum behind tau-targeted therapeutics as the next major treatment strategy.
🔹 Continued importance of amyloid-targeting therapies, particularly when used in the earliest stages of disease.
🔹 Increasing focus on combination approaches that address multiple disease mechanisms rather than relying on a single target.
🔹 Advances in biomarkers and early diagnosis, enabling more personalized treatment strategies.

As the field moves toward precision medicine, high-quality research tools remain essential for biomarker discovery, target validation, and therapeutic development.

At Anogen – Yes Biotech Laboratories, we are proud to support neuroscience research with a broad portfolio of high-quality antibodies, recombinant proteins, ELISA kits, and immunoassay reagents, helping researchers advance the next generation of Alzheimer's diagnostics and therapeutics.

Read the full article here: https://www.biospace.com/drug-development/aaic-2026-tau-targeted-alzheimers-treatments-heat-up-while-amyloid-therapies-persist

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.

07/15/2026

Alzheimer's research continues to evolve, with advances in diagnosis, treatment, and disease monitoring bringing new hope for patients and families.

Key highlights from the latest updates include:

🔹 Blood-based biomarker tests are playing an increasingly important role in supporting earlier Alzheimer's diagnosis, alongside PET imaging and CSF testing.
🔹 Leqembi® and Kisunla™ remain the only FDA-approved disease-modifying therapies for selected patients with early-stage Alzheimer's disease, with ongoing studies evaluating their long-term effectiveness and safety.
🔹 Research is expanding beyond amyloid, with promising developments in tau-targeted therapies, brain-shuttle antibody technology, combination treatments, and prevention studies.
🔹 Biomarker-guided diagnosis and personalized treatment strategies continue to shape the future of Alzheimer's care.

As our understanding of Alzheimer's disease grows, high-quality research reagents remain essential for biomarker discovery, target validation, and therapeutic development.

At Anogen, we're proud to support neuroscience research with a broad portfolio of monoclonal antibodies, recombinant proteins, and immunoassay solutions.

Read the full article here: https://losaltosneurology.com/2026/07/11/summer-2026-alzheimers-disease-updates/

A neurologist reviews 2026 Alzheimer’s advances, including new blood tests, Leqembi, Kisunla, ARIA safety, prevention trials, and emerging tau therapies.

07/08/2026

The 2026 Alzheimer's disease drug development pipeline highlights encouraging progress in the search for new therapies:

🔹 158 candidate drugs are currently being evaluated across 192 active clinical trials
🔹 73% of therapies are disease-targeting, aiming to slow or prevent disease progression
🔹 35% of pipeline drugs are repurposed therapies, offering new opportunities through existing compounds
🔹 More than 54,000 participants are needed to support ongoing clinical studies
🔹 The biopharmaceutical industry sponsors 59% of all trials and 72% of Phase 3 studies

Beyond anti-amyloid therapies, researchers are increasingly targeting inflammation, immune dysfunction, tau pathology, metabolism, neuroprotection, and other biological pathways, reflecting a more diverse and promising therapeutic landscape.

At Anogen, we are proud to support neuroscience and Alzheimer's research with high-quality monoclonal antibodies, recombinant proteins, and immunoassay reagents for biomarker discovery and translational research.

Read the full article here: https://pubmed.ncbi.nlm.nih.gov/42095064/

The AD drug development pipeline has a growing number of trials and drugs in trials. A diverse array of AD pathophysiological processes is being addressed by drugs in trials.

06/24/2026

📈 The Anti-TNF-α monoclonal antibody market continues to demonstrate strong growth potential, driven by the increasing prevalence of autoimmune and inflammatory diseases worldwide.

Anti-TNF therapies remain a cornerstone in the treatment of conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease. At the same time, several key trends are shaping the future of this market:
🔹 Expansion of biosimilar products, improving accessibility and affordability
🔹 Growing adoption of personalized medicine approaches
🔹 Increased use of digital health tools for patient monitoring and treatment management
🔹 Development of combination therapies to enhance clinical outcomes
🔹 Continued investment in biologics and next-generation antibody technologies

As demand for targeted immunotherapies continues to rise, anti-TNF-α antibodies remain an important focus for innovation, clinical research, and commercial growth.

Read the full article: https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market

At Anogen, we are proud to support immunology and inflammation research with a broad portfolio of monoclonal antibodies, ELISA kits, and research reagents.

Monoclonal antibodies market size was valued at $267.6B in 2025 and is projected to grow from $294.1B in 2026 to $547.3B by 2033, at a CAGR of 9.3%

06/17/2026

The Alzheimer's treatment landscape is evolving rapidly, with researchers expanding beyond traditional symptom management toward therapies that may slow disease progression.

Recent milestones include the FDA approvals of Leqembi® (lecanemab) and Kisunla™ (donanemab), the first disease-modifying treatments designed to target amyloid-beta pathology in Alzheimer's disease.

Looking ahead, scientists are actively exploring:

🔹 Next-generation amyloid-clearing therapies
🔹 Novel therapeutic targets beyond amyloid, including neuroinflammation and neuroprotection
🔹 Oral treatment options to improve accessibility and patient convenience
🔹 Non-invasive approaches such as brain stimulation and focused ultrasound
🔹 Lifestyle interventions that may help reduce Alzheimer's risk

With nearly 200 clinical trials evaluating more than 150 investigational therapies, the future of Alzheimer's research is becoming increasingly diverse and promising. As our understanding of the disease continues to grow, innovative therapeutic strategies may help transform the way Alzheimer's is treated in the years ahead.

Source: BrightFocus Foundation
https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-landscape-a-2026-forecast/

Learn about the treatments landscape for Alzheimer’s in 2026 and beyond.

06/10/2026

Tiziana Life Sciences recently announced positive updated clinical data for its lead candidate, intranasal foralumab, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

Key highlights from the ongoing Expanded Access Program include:

✔ Disease improvement or stabilization observed in all 14 treated patients within 6 months
✔ Favorable trends in disability stabilization (EDSS)
✔ Clinically meaningful improvements in fatigue scores (MFIS)
✔ Continued demonstration of a favorable safety and tolerability profile

Foralumab is a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells through intranasal administration, representing a novel approach to modulating neuroinflammation without broad systemic immunosuppression.

With limited treatment options currently available for na-SPMS, these findings further support the potential of targeted immunomodulatory therapies in neurodegenerative and neuroinflammatory diseases.

Read more: https://www.tizianalifesciences.com/tiziana-announces-new-positive-clinical-data-for-intranasal-foralumab-in-non-active-secondary-progressive-multiple-sclerosis/

Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS).

06/03/2026

🔬 Anti-IL-8 antibodies continue to emerge as promising therapeutic candidates across oncology and inflammatory diseases.

In oncology, IL-8 blockade has been investigated as a strategy to overcome tumor-associated immune suppression and enhance responses to checkpoint inhibitors. Anti-IL-8 antibodies such as BMS-986253 have demonstrated the ability to modulate the tumor microenvironment and support antitumor immune activity.

Beyond cancer, the long-acting anti-IL-8 antibody AMY109 is advancing in endometriosis research. Preclinical and early clinical studies suggest that targeting IL-8 may reduce inflammation, fibrosis, and lesion development while maintaining a favorable safety profile.

As understanding of IL-8 biology expands, anti-IL-8 therapeutics may offer new opportunities for treating both cancer and chronic inflammatory diseases.

Reference:
BMS-986253 / HuMax-IL8 Phase I trial (PubMed), https://pubmed.ncbi.nlm.nih.gov/31488216/
Melanoma immunotherapy studies ESMO Report https://dailyreporter.esmo.org/esmo-immuno-oncology-congress-2022/other-news/preliminary-activity-is-reported-with-an-anti-il-8-monoclonal-antibody-plus-nivolumab-in-melanoma?utm_source=chatgpt.com

Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors

05/27/2026

🧠 New research highlights the potential role of immunotherapy in healthy brain aging.

Tiziana Life Sciences recently reported preclinical data showing that nasal anti-CD3 therapy improved cognition associated with aging, supporting growing interest in targeting neuroinflammation for cognitive health.

Key highlights:

✔ Improved cognition observed in aging models
✔ Non-invasive nasal anti-CD3 immunotherapy approach
✔ Potential applications in neuroinflammation and age-related cognitive decline

These findings continue to support the emerging connection between immune modulation and brain health research.

🔗 Read more: https://www.globenewswire.com/news-release/2026/04/01/3266479/0/en/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging.html

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate,...

05/20/2026

Tiziana Life Sciences recently reported reduced brain inflammation in patients with non-active secondary progressive multiple sclerosis (SPMS) treated with intranasal foralumab, an investigational anti-CD3 monoclonal antibody therapy.

Key findings include:
✔ Reduction of microglial activation observed through PET imaging
✔ Potential non-invasive immunomodulatory approach for neuroinflammatory diseases
✔ Continued progress in multiple sclerosis and CNS inflammation research

These findings highlight the growing interest in targeted immune therapies for neurological disorders and the important role of inflammation in disease progression.

🔗 Read more: https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-reports-reduced-brain-inflammation-multiple-system